Physician

Arunas Urbonas, M.D.

According to 2025 Medicare claims, Arunas Urbonas, M.D. (NPI: 1790771004) practices nephrology in the Valdosta, GA market, with the plurality of this provider's patient population coming from Lowndes, GA. This provider's primary affiliated billing organization is ARUNAS URBONAS MD PLLC (NPI: 1003983883; TIN: 27-0075893) and primary practice location at 31602-1718.

Urbonas' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 921 traditional Medicare patients, billed 4,570 HCPCS/CPT codes, and received $322,152 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 3,229 prescription claims across 557 beneficiaries totaling $199,326 in drug costs, led by Jardiance (Empagliflozin). DME data shows 60 claims. Open Payments data shows 2 records totaling $49. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have fallen sharply in recent years, from $221,949 to $199,326. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,260	8,832	$455,241
2016	1,330	8,993	$452,964
2017	1,311	7,926	$462,220
2018	1,399	6,883	$617,329
2019	1,447	8,212	$798,483
2020	1,152	5,337	$366,268
2021	957	3,490	$300,473
2022	984	3,434	$307,693
2023	1,034	4,321	$349,978
2024	921	4,570	$322,152

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	554	5,391	$221,949
2016	522	4,592	$174,844
2017	587	4,928	$334,832
2018	657	5,239	$328,527
2019	693	6,389	$489,555
2020	576	4,716	$374,073
2021	482	3,044	$163,012
2022	481	2,712	$166,726
2023	540	3,026	$157,606
2024	557	3,229	$199,326

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	169	$9,687
2016	N/R	200	$15,456
2017	N/R	189	$12,259
2018	N/R	178	$6,427
2019	N/R	292	$15,340
2020	N/R	247	$12,295
2021	N/R	217	$6,798
2022	N/R	206	$9,128
2023	N/R	183	$7,698
2024	N/R	60	$1,048

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	124	124	$121
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	127	211	$101
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	748	1,939	$90
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	152	876	$62
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	557	868	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	98	3,601	$71,126
Farxiga	Dapagliflozin Propanediol	25	1,080	$19,310
Veltassa	Patiromer Calcium Sorbitex	19	656	$17,396
Paricalcitol	Paricalcitol	34	1,690	$4,503
Potassium Chloride	Potassium Chloride	270	12,803	$4,148

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	20	$358
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	11	$261
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	12	$229
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	17	$201

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$49	AKEBIA THERAPEUTICS INC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Arunas Urbonas, M.D.?

Tedicare shows public-source Medicare data for Arunas Urbonas, M.D. (NPI 1790771004), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Arunas Urbonas, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Arunas Urbonas, M.D.?

Arunas Urbonas, M.D. is linked to ARUNAS URBONAS MD PLLC (billing NPI 1003983883) in the available physician profile data.

Does Arunas Urbonas, M.D. have Open Payments data?

Arunas Urbonas, M.D. has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.